Romeo Isidro, MD
Psychiatry · Northridge, CANPI 1558393660
Payments from drug & device makers
Across 1,638 payments — averaging $553.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$443K
- Teva Pharmaceuticals USA, Inc.$215K
- Acadia Pharmaceuticals Inc$147K
- AbbVie$50K
- Alkermes, Inc.$45K
- Otsuka America Pharmaceutical, Inc.$803
- plus $5K from 24 others
What the payments were for
- Consulting fees$41,8855%
- Speaking & faculty fees$763,76984%
- Travel & lodging$62,5687%
- Food & beverage$38,1974%
- Education$4130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 509 | $443,356 |
| Teva Pharmaceuticals USA, Inc. | 315 | $215,223 |
| Acadia Pharmaceuticals Inc | 261 | $147,249 |
| AbbVie(2 entities) | 163 | $49,690 |
| Alkermes, Inc. | 103 | $45,455 |
| Otsuka America Pharmaceutical, Inc. | 36 | $803 |
| Lundbeck LLC | 36 | $768 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $666 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $617 |
| Bausch Health US, LLC | 24 | $500 |
| E.r. Squibb & Sons, L.L.C. | 19 | $500 |
| Avanir Pharmaceuticals, Inc. | 18 | $295 |
| Johnson & Johnson | 11 | $269 |
| Vanda Pharmaceuticals Inc. | 6 | $175 |
| Sunovion Pharmaceuticals Inc. | 16 | $163 |
| Almatica Pharma LLC | 6 | $159 |
| Indivior Inc. | 6 | $141 |
| Corium, LLC | 6 | $124 |
| Merck | 5 | $121 |
| Axsome Therapeutics, Inc. | 4 | $108 |
| Alpha Cognition USA, Inc. | 6 | $99 |
| Neuronetics, Inc. | 2 | $88 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Adlon Therapeutics L.p. | 3 | $45 |
| Sun Pharmaceutical Industries Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| Ironshore Pharmaceuticals Inc. | 1 | $23 |
| Eisai Inc. | 1 | $20 |
| Tris Pharma Inc | 1 | $17 |
| Luye Pharma (USA) Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$906,831 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 138 | $1,048,028 |
| NuplazidPimavanserin Tartrate | 12 | $62,128 |
| VraylarCariprazine Hcl | 35 | $59,656 |
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $19,750 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $19,728 |
| Vilazodone Hcl | 35 | $7,164 |
| Divalproex Sodium ErDivalproex Sodium | 41 | $3,260 |
| Aripiprazole | 69 | $3,227 |
| Escitalopram Oxalate | 220 | $2,838 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 28 | $2,800 |
| Quetiapine Fumarate | 187 | $2,761 |
| Duloxetine Hcl | 121 | $2,176 |
| Mirtazapine | 50 | $968 |
| Alprazolam | 192 | $914 |
| Oxazepam | 13 | $902 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $443,356 | $1,048,028138 claims |
| Acadia Pharmaceuticals IncNuplazid | $147,249 | $62,12812 claims |
| AbbVieVraylar | $49,690 | $59,65635 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $295 | $19,75016 claims |
| Alkermes, Inc.Lybalvi | $45,455 | $19,72815 claims |
| Almatica Pharma LLCSertraline Hcl | $159 | $31631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Northridge
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.